Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

This publication has 21 references indexed in Scilit:

• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
  International Journal of Cancer, 2010
• Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition
  Onkologie, 2010
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2007
• Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
  The Oncologist, 2007
• Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
  Journal of Thoracic Oncology, 2007
• Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2007
• Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
  Clinical Cancer Research, 2006
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
  JNCI Journal of the National Cancer Institute, 2005